More importantly, we found that CD163 was differentially expressed in several types of breast cancer tissues, with a significantly higher proportion in triple-negative breast cancer tissues than in luminal and Her2-positive breast cancer tissues (Fig. 1B, C). This evidence concerns the gene CD163 and triple-negative breast carcinoma.